Nintedanib ‘ Superior ’ to Bevacizumab for Mesothelioma Treatment
Researchers in Austria, Germany and Hungary have added to the growing belief that the anti-cancer drug nintedanib may soon become a significant part of standard-of-care treatment for malignant pleural mesothelioma.
In their study published recently in Clinical Cancer Research, nintedanib demonstrated an ability to inhibit the growth and the migration of mesothelioma tumor cells effectively in animal models.
“This is a step in the right direction, another part of the evolutionary process of treatment advancements with this difficult disease,” Dr. Balazs Hegedus, department of thoracic surgery, University of Duisburg-Essen, told Asbestos.com. “This is an important finding.”
Nintedanib, also known by brand names Ofev and Vargetef, works by targeting a specific molecule expressed by most mesothelioma tumor cells. It functions much like bevacizumab (Avastin), one of the world’s best-selling cancer drugs, but it does so more effectively, according to this latest study.
“Importantly, this anti-tumor effect of nintedanib in experimental animals was stronger than that of bevacizumab,” Dr. Balazs Dome, head of the Translational Thoracic Oncology Program at the Medical University of Vienna in Austria said. “A key message is that nintedanib be considered superior as part of systemic anti-tumor therapy.”
Nintedanib Smothers Tumor Cells
Nintedanib inhibits tumor growth by denying cancer cells the oxygen and nutrients they need.
The drug is already approved for use with p...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Matt Mauney Source Type: news
More News: Asbestosis | Austria Health | Avastin | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | France Health | Germany Health | Hungary Health | Lung Cancer | Mesothelioma | Nutrition | Study | Texas University | UK Health | USA Health